RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Investigation

• Publication date

  2016-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI87033PMID 27454289PMCID PMC4966309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deciphering the BRCA1 Tumor Suppressor Network*

  2015cited by this paper
• A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

  2015cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells

  2015cited by this paper
• The scanning mechanism of eukaryotic translation initiation.

  2014cited by this paper
• Targeting Hepatitis B Virus With CRISPR/Cas9

  2014influential reference
• ATL

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

  2014cited by this paper
• Ovarian cancer

  2014cited by this paper
• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  2013cited by this paper
• Mechanisms of resistance to therapies targeting BRCA-mutant cancers

  2013cited by this paper
• Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

  2013influential reference
• BRCA1 is required for postreplication repair after UV-induced DNA damage.

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• BRCA1 and BRCA2: different roles in a common pathway of genome protection

  2011cited by this paper
• BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity

  2011cited by this paper
• BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

  2011cited by this paper
• 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

  2010cited by this paper
• BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• Translational regulation of gene expression during conditions of cell stress.

  2010cited by this paper
• BRCA1 and its toolbox for the maintenance of genome integrity

  2010cited by this paper
• Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2

  2010cited by this paper
• 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.

  2010cited by this paper
• Optimal treatment for relapsing ovarian cancer.

  2010cited by this paper
• Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes.

  2009cited by this paper
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response

  2007cited by this paper
• RAP80 Targets BRCA1 to Specific Ubiquitin Structures at DNA Damage Sites

  2007cited by this paper
• Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response

  2007cited by this paper
• The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon

  2006cited by this paper
• BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

  2006cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• The BRCA1 RING and BRCT Domains Cooperate in Targeting BRCA1 to Ionizing Radiation-induced Nuclear Foci*

  2005cited by this paper
• Molecular mechanisms of translational control

  2004cited by this paper
• BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

  2003cited by this paper
• Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology

  2003cited by this paper
• BARD1 Induces BRCA1 Intranuclear Foci Formation by Increasing RING-dependent BRCA1 Nuclear Import and Inhibiting BRCA1 Nuclear Export*

  2002cited by this paper
• The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons.

  2002cited by this paper
• Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development

  2001cited by this paper
• Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.

  2001cited by this paper
• Constraints on reinitiation of translation in mammals.

  2001cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• Constitutive activation of pp125fak in newly isolated human breast cancer cell lines

  1999cited by this paper
• BRCA1 and BRCA2 in breast cancer

  1999cited by this paper
• The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

  1995cited by this paper
• Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.

  1995cited by this paper
• Inherited breast and ovarian cancer.

  1995cited by this paper
• Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families

  1994cited by this paper
• Molecular genetics for the clinician

  1993cited by this paper
• Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs

  1989cited by this paper

• A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study

  2026cites this paper
• microRNA 146a suppresses tumor progression and enhances therapeutic sensitivity by targeting the EGFR pathway in BRCA1-associated basal-like breast cancers

  2025cites this paper
• Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers

  2025cites this paper
• Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma

  2025cites this paper
• An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance

  2025cites this paper
• Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer

  2025cites this paper
• Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma

  2025cites this paper
• gBRCA1 and gBRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.

  2025cites this paper
• DNA repair and the contribution to chemotherapy resistance

  2025cites this paper
• BRCA1 and BRCA2 in DNA damage and replication stress response: Insights into their functions, mechanisms, and implications for cancer treatment.

  2025cites this paper
• Genome-wide CRISPR activation screen identifies ARL11 as a sensitivity determinant of PARP inhibitor therapy

  2025cites this paper
• Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

  2025cites this paper
• Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer

  2025cites this paper
• Overexpressed NEK2 contributes to progression and cisplatin resistance through activating the Wnt/β-catenin signaling pathway in cervical cancer

  2025cites this paper
• Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas

  2024cites this paper
• BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality

  2024cites this paper
• Evaluation of the Oncomine Comprehensive Assay Plus NGS Panel and the OncoScan CNV Assay for Homologous Recombination Deficiency Detection

  2024cites this paper
• Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors

  2024cites this paper
• Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

  2024cites this paper
• Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.

  2024cites this paper
• FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer

  2024cites this paper
• A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer

  2024cites this paper
• How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature

  2024cites this paper
• Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers

  2024cites this paper
• Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient

  2024cites this paper
• Current proteomics methods applicable to dissecting the DNA damage response

  2023cites this paper
• PARP Inhibitors in Breast and Ovarian Cancer

  2023cites this paper
• Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

  2023cites this paper
• Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities

  2023cites this paper
• Mechanisms of PARP Inhibitor Resistance.

  2023cites this paper
• Hexyl-pentynoic acid serves as a novel radiosensitizer for breast cancer by inhibiting UCHL3-dependent Rad51 deubiquitination

  2023cites this paper
• Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options

  2023cites this paper
• Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer

  2023cites this paper
• RNF126, 168 and CUL1: The Potential Utilization of Multi-Functional E3 Ubiquitin Ligases in Genome Maintenance for Cancer Therapy

  2023cites this paper
• Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

  2023cites this paper
• PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.

  2023cites this paper
• A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant

  2023cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• RNAi Screening Uncovers a Synthetic Sick Interaction between CtIP and the BARD1 Tumor Suppressor

  2022cites this paper
• Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

  2022cites this paper
• Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells.

  2022cites this paper
• Opinion: PARP inhibitors in cancer—what do we still need to know?

  2022cites this paper
• Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance

  2022cites this paper
• Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?

  2021cites this paper
• Small‐molecule Effectors of DNA Repair Proteins: Applications for Development of Cancer Therapeutics and Research

  2021cites this paper
• RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage

  2021cites this paper
• Two redundant ubiquitin‐dependent pathways of BRCA1 localization to DNA damage sites

  2021cites this paper
• Is it a wrap? Nucleosome interactions of the BRCA1-binding partner, BARD1, steal the scene

  2021cites this paper
• Tackling PARP inhibitor resistance.

  2021cites this paper
• A protein interaction landscape of breast cancer

  2021cites this paper
• Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape

  2021cites this paper
• BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.

  2020cites this paper
• 1 BARD 1 and breast cancer : the possibility of creating 2 screening tests and new preventive and therapeutic 3 pathways for predisposed women 4

  2020cites this paper
• Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells

  2020cites this paper
• RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers

  2020cites this paper
• Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks

  2020cites this paper
• Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation

  2020cites this paper
• The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication

  2020cites this paper
• BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.

  2020cites this paper
• BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women

  2020cites this paper
• Genomic profiling of platinum-resistant ovarian cancer: the road into druggable targets.

  2020cites this paper
• New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer

  2020cites this paper
• BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis

  2020cites this paper
• LESSONS LEARNED FROM UNDERSTANDING CHEMOTHERAPY RESISTANCE IN EPITHELIAL TUBO-OVARIAN CARCINOMA FROM BRCA1 AND BRCA2 MUTATION CARRIERS.

  2020cites this paper
• PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

  2020cites this paper
• PARP inhibitor resistance: the underlying mechanisms and clinical implications

  2020cites this paper
• DBC1 Regulates p53 Stability via Inhibition of CBP-Dependent p53 Polyubiquitination

  2019cites this paper
• BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.

  2019cites this paper
• Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

  2019cites this paper
• PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.

  2019cites this paper
• BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

  2019cites this paper
• Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma

  2019cites this paper
• Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations

  2019cites this paper
• Non-homologous end joining is more important than proton linear energy transfer in dictating cell death.

  2019cites this paper
• Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.

  2018cites this paper
• Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer

  2018cites this paper
• ATL

  2018cites this paper
• “Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion

  2018cites this paper
• Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.

  2018cites this paper
• Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review

  2018cites this paper
• BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance

  2018cites this paper
• Reverse the Resistance to PARP Inhibitors

  2017influential citation
• Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review

  2017cites this paper
• Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.

  2017cites this paper
• 53BP1 regulates dna double-strand break repair in a mouse “BRCA-like” model by a non-resection mechanism

  2017cites this paper
• The bloom syndrome protein, BLM, inhibits homologous recombination by disrupting RAD51 nucleoprotein filaments

  2017cites this paper
• BRCA1 and BRCA2: two genes, multiple clinical applications

  2017cites this paper
• Histone ubiquitination in the DNA damage response.

  2017cites this paper
• Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

  2017cites this paper
• BRCA1 reversion mutation acquired after treatment identified by liquid biopsy

  2017cites this paper
• Biochemical and biophysical characterization of ruthenation of BRCA1 RING protein by RAPTA complexes and its E3 ubiquitin ligase activity.

  2017cites this paper
• Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium

  2017cites this paper
• Synthetic lethality: the road to novel therapies for breast cancer.

  2016cites this paper
• BRCA1 loses the ring but lords over resistance.

  2016cites this paper
• 53BP1 ablation rescues genomic instability in mice expressing ‘RING‐less’ BRCA1

  2016cites this paper
• An unexpected product from a 2 – base pair deletion

  2016cites this paper
• Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin

  2016cites this paper
• Family-Specific Variants and the Limits of Human Genetics.

  2016cites this paper
• Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.

  2016cites this paper
• The BRCA1 Ubiquitin ligase function sets a new trend for remodelling in DNA repair

  2016influential citation